Diarrhea

2024-2025: Sales growth of diarrhea remedies in Russia by 19.6% to ₽42,3 billion

By the end of 2024, the Russian market for antidiarrheal medicines reached ₽42,3 billion in retail prices, showing an increase of 19.6% compared to 2023. In physical terms, consumers purchased 138.8 million packages of A07 Group drugs, which is 1.8% less than the previous year. The data indicate an ongoing increase in the average cost of medicines with a decrease in physical sales volumes. This became known on August 6, 2025.

According to RNC Pharma, in the first half of 2025, Russians spent ₽22,6 billion on anti-diarrheal drugs, which exceeds the same figure in 2024 by 16.7%. In physical terms, 65.5 million packages of medicines of this category were sold, but this figure decreased by 1.5% compared to January-June 2024.

𝓲

Фото: Freepik

Rating of the best-selling antidiarrheal drugs in Russia for the first half of 2025 in terms of cash sales:

1. Linex (Sandoz) - market share 10.4%, sales growth 27%
2. Enterosgel (Farmasil) - market share 10.2%, sales growth 15%
3. Enterol ("Biocodex") - market share 8.7%, sales growth 42%
4. Polisorb (Polisorb) - market share 8.2%, sales growth 11%
5. Alfa Normix (Alfasigma) - market share 6.5%, sales growth 40%
6. Enterofuril (Bosnalek) - market share 6.1%, sales growth 3%
7. Bifiform ("GSK") - market share 6.1%, sales growth 5%
8. Loperamide ("Akrikhin" + 11 companies) - market share 4.4%, sales growth 15%
9. Hilak Forte (Teva) - market share 4.3%, sales growth 17%
10. Smekta (Ipsen) - market share 3.8%, sales growth 19%

Structural market analysis shows the dominance of two major drug subgroups. Means that regulate the balance of intestinal microflora and intestinal adsorbents together form more than 66% of the total sales volume. Antidiarrheal and intestinal antimicrobials account for 18.7% of the market in value terms.

In physical terms, adsorbents occupy the leading positions - in the six months of 2025, buyers purchased over 27 million packages of such drugs. At the same time, sales decreased by 7% over the year, which is associated with a decrease in interest in activated carbon-based drugs.^[1]

Notes